Serum Institute of India to start phase II trials of Oxford-AstraZeneca vaccine

New Delhi: The Serum Institute of India (SII), which has partnered with AstraZeneca for manufacturing the COVID-19 vaccine candidate developed by the University of Oxford, has said that it would start soon phase 2 trials of the COVID vaccine.

The SII also asserted that it has shortlisted 10 centres across India to host Phases 2 and 3 human clinical trials of the Oxford University developed COVID-19 vaccine.

This comes a day after the national expert group on vaccine administration for COVID-19 met representatives of leading domestic manufactures, including SII, Bharat Biotech and Zydus Cadila, to take inputs about the present stage of various candidate vaccines as well as their expectations from the government.

The meeting was chaired by Niti Aayog member V.K Paul and co-chaired by Union Health Secretary Rajesh Bhushan.

Meanwhile, with a spike of 55,079 cases and 876 fatalities in the last 24 hours, India’s tally of coronvirus cases rose to 27,02,743, including 6,73,166 active cases, 19,77,780 discharged or migrated and 51,797 deaths.

 

Asianet.in/NewsDesk: Asianet Online